Ciara Hanley1, Jeannie Callum2,3, Keyvan Karkouti4,5,6, Justyna Bartoszko7. 1. Department of Anesthesia, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 2. Department of Pathology and Molecular Medicine, Kingston Health Sciences Centre, Toronto, ON, Canada. 3. Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. 4. Department of Anesthesia and Pain Management, Sinai Health System, Women's College Hospital, University Health Network, Toronto, ON, Canada. 5. Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, University of Toronto, 200 Elizabeth Street 3EN-464, Toronto, ON, M5G 2C4, Canada. 6. Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada. 7. Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, University of Toronto, 200 Elizabeth Street 3EN-464, Toronto, ON, M5G 2C4, Canada. justyna.bartoszko@uhn.ca.
Abstract
PURPOSE: Intravascular fluids are a necessary and universal component of cardiac surgical patient care. Both crystalloids and colloids are used to maintain or restore circulating plasma volume and ensure adequate organ perfusion. In Canada, human albumin solution (5% or 25% concentration) is a colloid commonly used for this purpose. In this narrative review, we discuss albumin supply in Canada, explore the perceived advantages of albumin, and describe the clinical literature supporting and refuting albumin use over other fluids in the adult cardiac surgical population. SOURCE: We conducted a targeted search of PubMed, Embase, Medline, Web of Science, ProQuest Dissertations and Theses Global, the Cochrane Central Register of Controlled trials, and the Cochrane Database of Systematic Reviews. Search terms included albumin, colloid, cardiac surgery, bleeding, hemorrhage, transfusion, and cardiopulmonary bypass. PRINCIPAL FINDINGS: Albumin is produced from fractionated human plasma and imported into Canada from international suppliers at a cost of approximately $21 million CAD per annum. While it is widely used in cardiac surgical patients across the country, it is approximately 30-times more expensive than equivalent doses of balanced crystalloid solutions, with wide inter-institutional variability in use and no clear association with improved outcomes. There is a general lack of high-quality evidence for the superiority of albumin over crystalloids in this patient population, and conflicting evidence regarding safety. CONCLUSIONS: In cardiac surgical patients, albumin is widely utilized despite a lack of high- quality evidence supporting its efficacy or safety. A well-designed randomized controlled trial is needed to clarify the role of albumin in cardiac surgical patients.
PURPOSE: Intravascular fluids are a necessary and universal component of cardiac surgical patient care. Both crystalloids and colloids are used to maintain or restore circulating plasma volume and ensure adequate organ perfusion. In Canada, human albumin solution (5% or 25% concentration) is a colloid commonly used for this purpose. In this narrative review, we discuss albumin supply in Canada, explore the perceived advantages of albumin, and describe the clinical literature supporting and refuting albumin use over other fluids in the adult cardiac surgical population. SOURCE: We conducted a targeted search of PubMed, Embase, Medline, Web of Science, ProQuest Dissertations and Theses Global, the Cochrane Central Register of Controlled trials, and the Cochrane Database of Systematic Reviews. Search terms included albumin, colloid, cardiac surgery, bleeding, hemorrhage, transfusion, and cardiopulmonary bypass. PRINCIPAL FINDINGS: Albumin is produced from fractionated human plasma and imported into Canada from international suppliers at a cost of approximately $21 million CAD per annum. While it is widely used in cardiac surgical patients across the country, it is approximately 30-times more expensive than equivalent doses of balanced crystalloid solutions, with wide inter-institutional variability in use and no clear association with improved outcomes. There is a general lack of high-quality evidence for the superiority of albumin over crystalloids in this patient population, and conflicting evidence regarding safety. CONCLUSIONS: In cardiac surgical patients, albumin is widely utilized despite a lack of high- quality evidence supporting its efficacy or safety. A well-designed randomized controlled trial is needed to clarify the role of albumin in cardiac surgical patients.
Authors: Simon Finfer; Rinaldo Bellomo; Neil Boyce; Julie French; John Myburgh; Robyn Norton Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: Eduardo A Osawa; Andrew Rhodes; Giovanni Landoni; Filomena R B G Galas; Julia T Fukushima; Clarice H L Park; Juliano P Almeida; Rosana E Nakamura; Tania M V Strabelli; Brunna Pileggi; Alcino C Leme; Evgeny Fominskiy; Yasser Sakr; Marta Lima; Rafael A Franco; Raquel P C Chan; Marilde A Piccioni; Priscilla Mendes; Suéllen R Menezes; Tatiana Bruno; Fabio A Gaiotto; Luiz A Lisboa; Luiz A O Dallan; Alexandre C Hueb; Pablo M Pomerantzeff; Roberto Kalil Filho; Fabio B Jatene; Jose Otavio Costa Auler Junior; Ludhmila A Hajjar Journal: Crit Care Med Date: 2016-04 Impact factor: 7.598